MIIST Therapeutics
Miist Therapeutics is pioneering a new standard in acute care with inhaled therapies that provide instant relief within seconds. Their proprietary platform targets the peripheral lung to deliver rapid and efficient drug absorption, surpassing traditional inhalers. The company is developing rapid-acting therapies for indications such as smoking cessation and migraine relief, leveraging innovative inhaler technology to achieve fast, safe, and effective treatment options.
Industries
Nr. of Employees
small (1-50)
MIIST Therapeutics
Alameda, California, United States, North America
Products
MST01 (smoking cessation program)
An inhaled smoking cessation program intended to provide immediate relief of cigarette cravings and a programmed dose-tapering regimen over 12 weeks; site claims clinical validation showing 93% craving elimination within 2 minutes.
MST02 (migraine program)
A preclinical inhaled migraine therapy program intended to deliver peak migraine relief within minutes via peripheral lung delivery.
MST01 (smoking cessation program)
An inhaled smoking cessation program intended to provide immediate relief of cigarette cravings and a programmed dose-tapering regimen over 12 weeks; site claims clinical validation showing 93% craving elimination within 2 minutes.
MST02 (migraine program)
A preclinical inhaled migraine therapy program intended to deliver peak migraine relief within minutes via peripheral lung delivery.
Services
End-to-end development of inhaled therapy programs using a proprietary inhaler platform, covering formulation, device dosing protocols, and progression through preclinical and clinical stages.
End-to-end development of inhaled therapy programs using a proprietary inhaler platform, covering formulation, device dosing protocols, and progression through preclinical and clinical stages.
Expertise Areas
- Inhaled drug delivery
- Acute-care rapid-acting therapeutics
- Particle engineering and aerosol science
- Inhalation formulation development
Key Technologies
- Aerosol particle size control
- Peripheral lung targeting
- Vibration-based aerosol generation
- Programmable inhaler dosing algorithms
News & Updates
Miist Therapeutics announced raising $7 million to develop instant-acting inhaled therapies, focusing on smoking cessation and migraine relief.
TechCrunch reports that Miist Therapeutics has raised $7 million to develop treatments for smoking cessation and migraines, utilizing their innovative inhaler platform.
Miist Therapeutics announced raising $7 million to develop instant-acting inhaled therapies, focusing on smoking cessation and migraine relief.
TechCrunch reports that Miist Therapeutics has raised $7 million to develop treatments for smoking cessation and migraines, utilizing their innovative inhaler platform.